國藥現代(600420.SH):山東百諾擬將注射用頭孢他啶阿維巴坦鈉(2.5g)上市許可及相關權益轉讓予國藥金石
格隆匯4月16日丨國藥現代(600420.SH)公佈,近日,全資子公司國藥集團汕頭金石製藥有限公司(簡稱國藥金石)與山東百諾醫藥股份有限公司(簡稱山東百諾)簽署了《藥品上市許可轉讓合同》,山東百諾將其所研發的注射用頭孢他啶阿維巴坦鈉(2.5g)上市許可及相關權益轉讓予國藥金石。上述藥品上市許可轉讓費用總額不超過人民幣2200萬元(含税)。
注射用頭孢他啶阿維巴坦鈉為頭孢菌素類抗感染藥物,是由頭孢他啶和阿維巴坦鈉組成的複方製劑,主要適用於複雜性腹腔內感染、醫院獲得性肺炎和呼吸機相關性肺炎等。
山東百諾的注射用頭孢他啶阿維巴坦鈉(2.5g)已向國家藥品監督管理局提出藥品上市許可申請,並獲得受理。根據CDE網站顯示,除原研廠家外,國內僅齊魯製藥有限公司於2021年9月獲批。根據米內網數據庫顯示,注射用頭孢他啶阿維巴坦鈉製劑產品在全國城市公立醫院銷售額2021年為4.04億元,2022年上半年為2.65億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.